SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the community discusses the launch of the $DOJE ETF, with some anticipating significant price movement. Talk centers around potential accumulation strategies and whether the ETF will trigger a major rally, although the launch may be delayed. There's also discussion around Dogecoin's long-term value and comparisons to other cryptocurrencies.

The project is a derivative of Fartcoin. The Fartcoin deployer has deployed this token because the President at Bone Fide Wealth tweeted about "A client just called and asked me if there’s going to be a Fartcoin ETF this year." Since the Elon narrative is has been running this one has come to existence. The token is following different narratives like Fartcoin, SPX500 and other big memes following the Trump narrative.

Elon Trump Fart

ETF500.X is trending as the community rallies, emphasizing its strength and long-term vision, particularly after the CEO departure. Discussions highlight the token as Solana's first ETF, with many proclaiming it as the best ETF ever. The community is focused on accumulation, anticipating a significant move.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

aTyr Pharma ($ATYR) is trending as traders anticipate Phase 3 data for its lead drug, efzofitimod, in mid-September, creating a high-stakes binary event. The community is buzzing with debate around the trial's design, potential outcomes, and the influence of figures like Martin Shkreli, with some expecting a short squeeze if results are positive. Bullish sentiment is fueled by recent analyst ratings and commercial hires, while bears point to past trial data and high implied volatility.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group (DJT) is trending amid heated discussions around the political motivations behind a recent tragedy, sparking intense debate within the community.  Users are clashing over affiliations and broader cultural grievances, with some pointing fingers and others calling for unity. The conversation highlights the deep divisions and sensitivities surrounding the symbol and its association with political figures.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as traders discuss potential volatility catalysts, including upcoming economic data and geopolitical tensions. Community members are weighing the potential for a market correction against the effects of contango on the ETF. Some traders are using UVIX to hedge long positions or speculating on short-term price movements.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as the community debates its potential, particularly against other cryptocurrencies like Dogecoin.  Discussions include its network security, privacy features, and upcoming ETF possibilities.  Some traders are watching key price levels for potential breakouts, while others express concerns about its historical performance.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include Core, Cognitive Adjacencies, and Network Software and Services. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Arista Networks is trending as the stock experiences volatility amidst analyst upgrades and price target adjustments, leading to community debate on its near-term direction. Discussions revolve around recent price drops being potential profit-taking opportunities or possible manipulation, while others point to strong data center growth prospects and AI networking as long-term bullish factors. Community members are actively trading options and debating entry points, particularly around key technical levels.

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.

GlucoTrack Inc

GCTK is trending due to a recent $20 million investment agreement, sparking community discussion about its potential impact and whether it signals a true turning point or further dilution. Community members are actively trading the stock, anticipating significant price movement based on the low float and upcoming conference, with some looking for a short squeeze. The stock is also being compared to other high-flying low floaters.

Apu, also known as Peepo or Helper, is a pepe-variant that is used to represent a much younger, kinder and more naive anthropomorphic frog. Fed up with low-effort memecoins, more often than not led by deceptive developers, Apu decided to create his own fairly launched, fully transparent coin: $APU – the one and only coin for all frens.

Apu Apustaja 

$APU.X is trending as the community rallies around the meme coin, highlighting its strong 4chan roots and community-driven nature. Conversations mention $APU.X's unique position within the memecoin landscape, with some drawing comparisons to other popular coins and its potential for significant growth. The recent listing on Hyperliquid and a guerilla marketing contest are adding to the buzz.

Volatility Shares Trust - 2x Bitcoin Strategy ETF

Volatility Shares 2x Bitcoin Strategy ETF

BITX is trending as traders assess Bitcoin's potential near all-time highs and its impact on leveraged ETFs. Community discussions revolve around market volatility, technical analysis, and the broader implications of economic policies. Concerns about potential market corrections and the influence of external factors such as political events are also driving interest in BITX.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates

ABSCI CORP (ABSI) delivered earnings and revenue surprises of -26.32% and -74.44%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

SAB Biotherapeutics (SABS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Absci Corporation (ABSI) Expected to Beat Earnings Estimates: Should You Buy?

ABSCI CORP (ABSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amgen (AMGN) Beats Q2 Earnings and Revenue Estimates

Amgen (AMGN) delivered earnings and revenue surprises of +14.45% and +3.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue Estimates

Syndax (SNDX) delivered earnings and revenue surprises of +17.00% and +30.74%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Coya Therapeutics, Inc. (COYA) Surges 10.7%: Is This an Indication of Further Gains?

Coya Therapeutics, Inc. (COYA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates

FDA Approval Race: AI-Powered Innovations Reshape the Healthcare Landscape

FDA Approval Race: AI-Powered Innovations Reshape the Healthcare Landscape FDA Approval Race: AI-Powered Innovations Reshape the Healthcare Landscape PR Newswire VANCOUVER, BC, Feb. 11, 2025 USA News...

Is AMD Stock a Buy, Sell, or Hold on HSBC’s Double Downgrade?

AMD stock fell after an analyst slashed his price target and rating on the stock due to Nvidia competition and weak AI GPU demand.

Absci Corp. shares gained over 4% in the previous session, drawing the most retail interest among biotech stocks on Stocktwits after the company announced a strategic partnership with AMD, which includes a $20 million investment pledge from the chipmaker.&nbsp;This investment, structured as a private investment in public equity (PIPE), reportedly marks AMD’s entry into life sciences, leveraging its AI chips for drug discovery.The collaboration aims to integrate AMD’s high-performance computing capabilities with Absci’s AI-powered de novo antibody design models.&nbsp;The partnership will be showcased at the upcoming 43rd Annual J.P. Morgan Healthcare Conference on Jan. 15, Absci said.Retail engagement on Stocktwits skyrocketed, with message volume surging by 36,900% on Wednesday.&nbsp;Sentiment on the platform for Absi was 'bullish' heading into Friday even as profit-taking set in, as the company revealed another partnership.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ABSI_sentiment_and_message_volume_Jan_10_premarket_c443462d4e.png" alt="ABSI sentiment and message volume Jan 10 premarket.png" width="1318" height="324"><figcaption>ABSI sentiment and message volume Jan 10 premarket as of 7:50 am ET | source: Stocktwits</figcaption></figure>Absci and Owkin announced they have teamed up to harness their advanced AI platforms to speed up the discovery and design of new medicines. The partnership will focus on creating treatments for cancer and other conditions like immune disorders and inflammation.&nbsp;<stembedurl>https://stocktwits.com/GeraldK75/message/599519367</stembedurl><stembedurl>https://stocktwits.com/J_The_Legend/message/599520163</stembedurl><stembedurl>https://stocktwits.com/GeraldK75/message/599508901</stembedurl>Adding to Wednesday’s optimism, Cathie Wood’s ARK Investment purchased 608,900 Absci shares, through its ARK Genomic Revolution ETF (ARKG), valued at over $1.9 million as of the last close.&nbsp;AI-driven drug discovery is a space being increasingly targeted by major tech players. Last year, Nvidia&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/top-biotech-stocks-with-highest-retail-chatter-in-2024/cJOEinNRjV">invested</a> $50 million in Recursion Pharmaceuticals for similar initiatives.KeyBanc lowered its price target for Absci to $5 from $6&nbsp;on Wednesday but maintained an ‘Overweight’ rating, citing the broader rebound in healthcare technology stocks following Donald Trump’s election.&nbsp;The brokerage said it sees opportunities in companies with strong balance sheets but warned of risks for those with limited profitability.&nbsp;Absci reported $127.1 million in cash and equivalents as of September 30, 2024, down from $145.2 million the previous quarter.Shares of the company remain down over 22% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Close up of scientist hand inoculating an agar plates with bacteria in microbiology lab | Image source: Getty Images

Small-Cap Biotech Absci Draws Heavy Attention On $20M AMD Investment Pledge, Retail's Bullish Despite Pre-Market Dip

The investment reportedly marks AMD’s entry into life sciences, leveraging its AI chips for drug discovery.

Equity

The investment reportedly marks AMD’s entry into life sciences, leveraging its AI chips for drug discovery.


Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs. The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.

ABSI
Absci Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ABSI News

ABSI Absci Corp